[1] LOK AS,MCMAHON BJ. The American Association for the Study of Liver Diseases(AASLD). Chronic hepatitis B:Update 2009[J]. Hepatology,2009,50(3):661-696. [2] European Association for the Study of the Liver. EASL clinical practice guidelines:Management of chronic hepatitis B[J]. J Hepatol,2009,50(2):227-242. [3] KEEFFE EB,DIETERICH DT,HAN SB,et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States:2008 Update[J]. Clin Gastroenterol Hepatol,2008,6(12):1315-1341. [4] SHIHA G,SARIN KS,IBRAHIM AE,et al. Liver fibrosis:consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)[J]. Hepatol Int, 2009,3(2):323-333. [5] LIAW YF,SUNG JJY,CHOW WC,et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease[J]. N Engl J Med,2004,351(15):1521-1531. [6] LIAW YF,LEUNG N,KAO JH,et al. Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2008 update[J]. Hepatol Int,2008,2(3):263-283. [7] LIN SM,YU ML,LEE CM,et al. Interferon therapy in HBeAg positive chronic hepatitis reduces cirrhosis and hepatocellular carcinoma[J]. J Hepatol,2007,46(1):45-52. [8] ILOEJE UH,YANG HI,SU J,et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load[J]. Gastroenterology,2006,130(3):678-686. [9] KIM SU,HAN KH,NAM CM,et al. Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites[J]. J Gastroenterol Hepatol,2008,23(11):1722-1727. [10] CHEN YC,CHU CM,YEH CT,et al. Natural course following the onset of cirrhosis in patients with chronic hepatitis B:a longterm follow-up study[J]. Hepatol Int, 2007,1(1):267-273. [11] CHU CM,LIAW YF. Hepatitis B virus-related cirrhosis: natural history and treatment[J]. Semin Liver Dis,2006,26(2):142-152. [12] SORRELL MF,BELONGIA EA,COSTA J,et al. National Institutes of Health Consensus Development Conference Statement:Management of hepatitis B[J]. Ann Intern Med, 2009,150(2):104-110. [13] CHEN CJ,YANG HI,SU J,et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA,2006,295(1):65-73. [14] CHOU YC,YU MW,WU CF,et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma[J]. Gut,2008,57(1):91-97. [15] KAPOOR D,GUPTAN RC,WAKIL SM,et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis[J]. J Hepatol,2000,33(2):308-312. [16] YAO FY,TERRAULT NA,FREISE C,et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation:A comparative study using a matched,untreated cohort[J]. Hepatology,2001,34(2):411-416. [17] FONTANA RJ,KEEFFE EB,CAREY W,et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B[J]. Liver Transplantation,2002,8(5):433-439. [18] HANN HW,FONTANA RJ,WRIGHT T,et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis[J]. Liver Transplantation,2003,9(1):49-56. [19] TSENG PL,LU SN,TUNG HD,et al. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis[J]. J Viral Hepat,2005,12(4):386-392. [20] DI MARCO V,MARZANO A,LAMPERTICO P,et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine[J]. Hepatology,2004,40(4):883-891. [21] SCHIFF ER,LAI CL,HADZIYANNIS S,et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre-and post-liver transplantation patients[J]. Hepatology,2003,38(6):1419-1427. [22] SCHIFF E,LAI CL,HADZIYANNIS S,et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B:final long-term results[J]. Liver Transpl,2007,13(3):349-60. [23] 梁静,韩涛,肖时湘,等. 替比夫定治疗乙型肝炎肝硬化的疗效观察[J]. 中华肝脏病杂志,2009,17(1):24-27. [24] BUSTER EH,HANSEN BE,BUTI M,et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis[J]. Hepatology, 2007,46(2):388-394. [25] LIAW YF. Hepatitis B virus replication and liver disease progression:the impact of antiviral therapy[J]. Antivir Ther,2006,11(16):669-679. [26] TERRAULT NA. Benefits and risks of combination therapy for hepatitis B[J]. Hepatology,2009,49(5 S):S122-128. |